Physician profile
David Desantis
NPI 1467447748
$1,109.70
in general payments reported to CMS, 2019-2025
23 companies · $763 in 2025
The $763 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $14.50 · 2021: $105 · 2022: $67.20 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $763.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $198.71 | 2025 | Fanapt |
| Abbvie INC. | $151.12 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $130.41 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.40 | 2022-2025 | Caplyta |
| Pfizer INC. | $75.31 | 2025 | |
| Gilead Sciences, INC. | $54.30 | 2019-2025 | |
| Lundbeck LLC | $51.37 | 2025 | Rexulti |
| Allergan, INC. | $44.51 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $37.93 | 2025 | Rexulti |
| Indivior INC. | $30.32 | 2025 | Sublocade |
| Alkermes, INC. | $27.71 | 2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $27.33 | 2025 | |
| Amgen INC. | $24.96 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $24.08 | 2025 | Austedo Xr |
| Axsome Therapeutics, INC. | $23.05 | 2025 | Auvelity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $20.70 | 2025 | Azstarys |
| Novo Nordisk INC | $19.12 | 2022 | |
| Coopersurgical, INC. | $18.35 | 2025 | Paragard T 380a |
| Astrazeneca Pharmaceuticals Lp | $15.66 | 2025 | Airsupra |
| Glaxosmithkline, LLC. | $15.42 | 2025 | Arexvy, Shingrix, Bexsero |
| Exact Sciences Corporation | $14.46 | 2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $14.23 | 2025 | Zoryve |
| Phathom Pharmaceuticals, INC. | $8.25 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Desantis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.